ArriVent's firmonertinib misses Phase 3 trial goal in lung cancer
ArriVent's Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed its primary progression-free survival endpoint, with independent review showing no meaningful improvement versus chemotherapy.